{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:24Z","timestamp":1779951744810,"version":"3.53.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite existing treatments of ocular myasthenia gravis (OMG), there remains a need for more effective therapies with fewer side effects. Telitacicept, a novel agent that simultaneously inhibits B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), represents a promising therapeutic candidate for OMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      In this study, telitacicept monotherapy or combination therapy was administered to three patients with OMG who had shown an inadequate response to, or were intolerant of, standard treatments. All patients demonstrated clinically significant improvement post-treatment. Specifically, both the Myasthenia Gravis Foundation of America-Quantitative Myasthenia Gravis (MGFA-QMG) and the Myasthenia Gravis Activities of Daily Living (MG-ADL) scores showed a marked reduction, indicating decreased disease severity and improved quality of life. Immunological assessments revealed an initial decline in CD19\n                      <jats:sup>+<\/jats:sup>\n                      B lymphocyte counts and acetylcholine receptor (AChR) antibody levels. Interestingly, despite well-controlled clinical symptoms, AChR antibody levels subsequently rebounded and stabilized. Furthermore, pulmonary infections in one patient were not established as causally related to telitacicept.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept monotherapy or combination treatment in OMG was associated with favorable clinical improvement and a mild adverse event profile, and its use can be tailored to the individual patient. However, larger-scale and longer-term studies are necessary to confirm these findings and fully establish the role of telitacicept in OMG management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1774173","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:16:01Z","timestamp":1779948961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Use of telitacicept for ocular myasthenia gravis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ali","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Zhengzhou University People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Henan University People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henan University People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Zhengzhou University People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Henan University People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Zhengzhou University People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Henan University People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhou","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Zhengzhou University People\u2019s Hospital","place":["Zhengzhou, China"]},{"name":"Department of Neurology, Henan University People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2025.101969","article-title":"Myasthenia gravis: mechanisms, clinical syndromes, and diagnosis","volume":"71","author":"Fecto","year":"2025","journal-title":"Dis Mon"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207642","article-title":"Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis: a systematic review and meta-analysis","volume":"101","author":"Fang","year":"2023","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.71157","article-title":"Add-on telitacicept significantly improves outcome of patients with refractory ocular myasthenia gravis a real-world case series","volume":"16","author":"Lin","year":"2026","journal-title":"Brain Behav"},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/WNO.0000000000000270","article-title":"Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231163819","article-title":"Immunotherapy for ocular myasthenia gravis: an observational study in Japan","volume":"16","author":"Narita","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000507853","article-title":"Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China","volume":"83","author":"Feng","year":"2020","journal-title":"Eur Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120330","article-title":"Relative change rate of anti-acetylcholine receptor antibodies concentration correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients","volume":"574","author":"Tian","year":"2025","journal-title":"Clin Chim Acta"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02603-y","article-title":"Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology","volume":"146","author":"Pham","year":"2023","journal-title":"Acta Neuropathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214150","article-title":"Subunit-specific immunodominance in clinically distinct populations with AChR+ myasthenia gravis: a multiparametric cross-sectional analysis","volume":"105","author":"Oved","year":"2025","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.4520","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (adapt): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1555068","article-title":"Real world study in Italian public hospital with efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors","volume":"16","author":"Sgarzi","year":"2025","journal-title":"Front Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a blys\/april dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:16:24Z","timestamp":1779948984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2026.1774173"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1774173","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1774173"}}